文献速递浆细胞疾病

冒烟型多发性骨髓瘤的基因组图谱识别疾病进展高风险患者

Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression.
PubMed 文献 · J Clin Oncol · 2020-05-22

该研究对214例冒烟型多发性骨髓瘤(SMM)患者进行下一代测序,其中166例肿瘤行全外显子测序(含5例连续样本),48例肿瘤行深度靶向测序。研究发现MAPK通路(KRAS和NRAS单核苷酸变异)、DNA修复通路(17p缺失、TP53和ATM单核苷酸变异)及MYC(易位或拷贝数变异)改变均为进展的独立危险因素,并在外部SMM队列中验证。APOBEC相关突变在进展患者中富集且与更短进展时间相关。

要点

  • 多数进展所需的遗传改变在SMM诊断时已获得。
  • MAPK通路、DNA修复通路及MYC改变为进展独立危险因素。
  • 具备上述三种特征中任一特征的患者进展至MM风险更高。

核心结论

  • SMM是遗传学成熟的实体,大多数驱动遗传改变已经发生,提示从意义未明的单克隆丙种球蛋白病到MM的遗传演化呈右偏模型。
  • 识别并外部验证了可区分进展至MM高风险患者的基因组预测因素,从而提高当前临床模型的精确性。

研究设计与样本

  • 研究采用下一代测序对214例SMM患者进行检测,其中166例肿瘤行全外显子测序(包括5例连续样本),48例肿瘤行深度靶向测序。
  • 在外部SMM队列中对发现进行验证。

主要发现

  • MAPK通路(KRAS和NRAS单核苷酸变异)、DNA修复通路(17p缺失、TP53和ATM单核苷酸变异)及MYC(易位或拷贝数变异)改变在考虑临床风险分期后均为进展的独立危险因素。
  • 在外部SMM队列中验证,具备上述三种特征中任一特征的患者进展至MM的风险更高。
  • APOBEC相关突变在进展患者中富集,并在本队列中与更短的进展时间相关。

关键数值与推荐

  • SMM年进展风险为10%。
  • MAPK通路改变包括KRAS和NRAS单核苷酸变异。
  • DNA修复通路改变包括17p缺失、TP53和ATM单核苷酸变异。
  • MYC改变包括易位或拷贝数变异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Smoldering multiple myeloma (SMM) is a precursor condition of multiple myeloma (MM) with a 10% annual risk of progression. Various prognostic models exist for risk stratification; however, those are based on solely clinical metrics. The discovery of genomic alterations that underlie disease progression to MM could improve current risk models. METHODS: We used next-generation sequencing to study 214 patients with SMM. We performed whole-exome sequencing on 166 tumors, including 5 with serial samples, and deep targeted sequencing on 48 tumors. RESULTS: We observed that most of the genetic alterations necessary for progression have already been acquired by the diagnosis of SMM. Particularly, we found that alterations of the mitogen-activated protein kinase pathway (KRAS and NRAS single nucleotide variants [SNVs]), the DNA repair pathway (deletion 17p, TP53, and ATM SNVs), and MYC (translocations or copy number variations) were all independent risk factors of progression after accounting for clinical risk staging. We validated these findings in an external SMM cohort by showing that patients who have any of these three features have a higher risk of progressing to MM. Moreover, APOBEC associated mutations were enriched in patients who progressed and were associated with a shorter time to progression in our cohort. CONCLUSION: SMM is a genetically mature entity whereby most driver genetic alterations have already occurred, which suggests the existence of a right-skewed model of genetic evolution from monoclonal gammopathy of undetermined significance to MM. We identified and externally validated genomic predictors of progression that could distinguish patients at high risk of progression to MM and, thus, improve on the precision of current clinical models.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bustoros M, Sklavenitis-Pistofidis R, Park J, et al. Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. J Clin Oncol. 2020. PMID: 32442065. doi:10.1200/JCO.20.00437

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。